It’s small consolation to someone facing retribution at work for their boss’ indiscretion, but if nothing else your question ...

Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant ...

Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more ...

Efficacy data remain consistent with previous disclosures, showing 10.3-month median PFS in all patients and 11.4-month median PFS in 2L ...

This study retrospectively analyzed ten pediatric patients with HOX-driven AML who received revumenib maintenance after HSCT at a single-center. The median age was 10 years (range: 1-18). 80% (8/10) ...

Journalist Amy Robach reflects on her journey—and how women like Rebecca are reclaiming their lives after diagnosis.

The standard measure of lesion count may matter less than the underlying biology driving treatment response in ...

Slowly tapering antidepressants with psychological support prevents depression relapse to a similar extent as continuing the medication, a new analysis shows.

The SERENA-6 trial shows a 54% reduced risk of death with camizestrant, with a median PFS of 16.6 months versus 9.2 months ...

TARGETED treatments for prostate cancer were a central theme at the European Society for Medical Oncology (ESMO) Congress ...

Deep and durable ongoing responses with median time on treatment of 15 months Company to accelerate development of PLN-101095 ...

When cells can’t destroy damaged proteins, a hidden backup system led by NRF1 steps in to prevent toxic buildup.